A randomized phase II trial evaluating the addition of low dose, short course sunitinib to docetaxel in advanced solid tumours

BACKGROUND: We previously reported that low-dose, short-course sunitinib prior to neoadjuvant doxorubicin-cyclophosphamide (AC) normalised tumour vasculature and improved perfusion, but resulted in neutropenia and delayed subsequent cycles in breast cancer patients. This study combined sunitinib wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Ang, Yvonne L. E., Ho, Gwo Fuang, Soo, Ross A., Sundar, Raghav, Tan, Sing Huang, Yong, Wei Peng, Ow, Samuel G. W., Lim, Joline S. J., Chong, Wan Qin, Soe, Phyu Pyar, Tai, Bee Choo, Wang, Lingzhi, Goh, Boon Cher, Lee, Soo-Chin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7672922/
https://www.ncbi.nlm.nih.gov/pubmed/33203399
http://dx.doi.org/10.1186/s12885-020-07616-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7672922/
https://www.ncbi.nlm.nih.gov/pubmed/33203399
http://dx.doi.org/10.1186/s12885-020-07616-4

Ejemplares similares